nodes	percent_of_prediction	percent_of_DWPC	metapath
Boceprevir—CTSV—Endosomal/Vacuolar pathway—HLA-E—Graves' disease	0.0413	0.0824	CbGpPWpGaD
Boceprevir—CTSL—Endosomal/Vacuolar pathway—HLA-E—Graves' disease	0.0413	0.0824	CbGpPWpGaD
Boceprevir—CTSV—Endosomal/Vacuolar pathway—HLA-B—Graves' disease	0.0294	0.0587	CbGpPWpGaD
Boceprevir—CTSL—Endosomal/Vacuolar pathway—HLA-B—Graves' disease	0.0294	0.0587	CbGpPWpGaD
Boceprevir—CTSS—Endosomal/Vacuolar pathway—HLA-E—Graves' disease	0.0282	0.0562	CbGpPWpGaD
Boceprevir—CTSV—eye—Graves' disease	0.0276	0.0794	CbGeAlD
Boceprevir—CTSV—Endosomal/Vacuolar pathway—HLA-A—Graves' disease	0.0273	0.0544	CbGpPWpGaD
Boceprevir—CTSL—Endosomal/Vacuolar pathway—HLA-A—Graves' disease	0.0273	0.0544	CbGpPWpGaD
Boceprevir—CMA1—connective tissue—Graves' disease	0.0254	0.0731	CbGeAlD
Boceprevir—CTSL—eye—Graves' disease	0.0225	0.0649	CbGeAlD
Boceprevir—CTSL—connective tissue—Graves' disease	0.0217	0.0625	CbGeAlD
Boceprevir—CTSV—pituitary gland—Graves' disease	0.0205	0.0589	CbGeAlD
Boceprevir—CTSV—adipose tissue—Graves' disease	0.0204	0.0587	CbGeAlD
Boceprevir—CTSS—Endosomal/Vacuolar pathway—HLA-B—Graves' disease	0.0201	0.04	CbGpPWpGaD
Boceprevir—CMA1—adipose tissue—Graves' disease	0.0195	0.0561	CbGeAlD
Boceprevir—CTSS—Endosomal/Vacuolar pathway—HLA-A—Graves' disease	0.0186	0.0371	CbGpPWpGaD
Boceprevir—CTSV—thyroid gland—Graves' disease	0.0176	0.0508	CbGeAlD
Boceprevir—CTSK—eye—Graves' disease	0.017	0.0489	CbGeAlD
Boceprevir—CTSL—pituitary gland—Graves' disease	0.0167	0.0481	CbGeAlD
Boceprevir—CTSL—adipose tissue—Graves' disease	0.0166	0.0479	CbGeAlD
Boceprevir—CTSK—connective tissue—Graves' disease	0.0163	0.0471	CbGeAlD
Boceprevir—CTSL—thyroid gland—Graves' disease	0.0144	0.0415	CbGeAlD
Boceprevir—CTSS—connective tissue—Graves' disease	0.0143	0.0413	CbGeAlD
Boceprevir—CTSK—pituitary gland—Graves' disease	0.0126	0.0363	CbGeAlD
Boceprevir—CTSK—adipose tissue—Graves' disease	0.0125	0.0361	CbGeAlD
Boceprevir—CTSS—pituitary gland—Graves' disease	0.011	0.0318	CbGeAlD
Boceprevir—CTSS—adipose tissue—Graves' disease	0.011	0.0317	CbGeAlD
Boceprevir—CTSK—thyroid gland—Graves' disease	0.0109	0.0313	CbGeAlD
Boceprevir—Skin ulcer—Propylthiouracil—Graves' disease	0.0108	0.0713	CcSEcCtD
Boceprevir—CTSS—thyroid gland—Graves' disease	0.00951	0.0274	CbGeAlD
Boceprevir—CTSL—Antigen processing-Cross presentation—HLA-E—Graves' disease	0.00844	0.0168	CbGpPWpGaD
Boceprevir—CTSV—Antigen processing-Cross presentation—HLA-E—Graves' disease	0.00844	0.0168	CbGpPWpGaD
Boceprevir—Lymphadenopathy—Methimazole—Graves' disease	0.00842	0.0556	CcSEcCtD
Boceprevir—Lymphadenopathy—Propylthiouracil—Graves' disease	0.00716	0.0473	CcSEcCtD
Boceprevir—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.00647	0.0427	CcSEcCtD
Boceprevir—CTSV—Antigen processing-Cross presentation—HLA-B—Graves' disease	0.00602	0.012	CbGpPWpGaD
Boceprevir—CTSL—Antigen processing-Cross presentation—HLA-B—Graves' disease	0.00602	0.012	CbGpPWpGaD
Boceprevir—CTSS—Antigen processing-Cross presentation—HLA-E—Graves' disease	0.00576	0.0115	CbGpPWpGaD
Boceprevir—CTSV—Antigen processing-Cross presentation—HLA-A—Graves' disease	0.00557	0.0111	CbGpPWpGaD
Boceprevir—CTSL—Antigen processing-Cross presentation—HLA-A—Graves' disease	0.00557	0.0111	CbGpPWpGaD
Boceprevir—CTSV—MHC class II antigen presentation—HLA-DQB1—Graves' disease	0.00552	0.011	CbGpPWpGaD
Boceprevir—CTSL—MHC class II antigen presentation—HLA-DQB1—Graves' disease	0.00552	0.011	CbGpPWpGaD
Boceprevir—CTSK—RANKL/RANK Signaling Pathway—ICAM1—Graves' disease	0.00547	0.0109	CbGpPWpGaD
Boceprevir—Neuropathy peripheral—Methimazole—Graves' disease	0.00542	0.0358	CcSEcCtD
Boceprevir—Agranulocytosis—Methimazole—Graves' disease	0.00516	0.0341	CcSEcCtD
Boceprevir—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00461	0.0305	CcSEcCtD
Boceprevir—CTSK—MHC class II antigen presentation—HLA-DQB1—Graves' disease	0.00457	0.00911	CbGpPWpGaD
Boceprevir—Agranulocytosis—Propylthiouracil—Graves' disease	0.00439	0.029	CcSEcCtD
Boceprevir—Alopecia—Methimazole—Graves' disease	0.00439	0.029	CcSEcCtD
Boceprevir—CTSL—MHC class II antigen presentation—HLA-DRB1—Graves' disease	0.00419	0.00836	CbGpPWpGaD
Boceprevir—CTSV—MHC class II antigen presentation—HLA-DRB1—Graves' disease	0.00419	0.00836	CbGpPWpGaD
Boceprevir—CTSS—Antigen processing-Cross presentation—HLA-B—Graves' disease	0.00411	0.00819	CbGpPWpGaD
Boceprevir—Vertigo—Methimazole—Graves' disease	0.00389	0.0257	CcSEcCtD
Boceprevir—Leukopenia—Methimazole—Graves' disease	0.00387	0.0256	CcSEcCtD
Boceprevir—CTSS—Antigen processing-Cross presentation—HLA-A—Graves' disease	0.0038	0.00759	CbGpPWpGaD
Boceprevir—CTSS—MHC class II antigen presentation—HLA-DQB1—Graves' disease	0.00376	0.00751	CbGpPWpGaD
Boceprevir—Alopecia—Propylthiouracil—Graves' disease	0.00373	0.0246	CcSEcCtD
Boceprevir—Arthralgia—Methimazole—Graves' disease	0.00368	0.0243	CcSEcCtD
Boceprevir—Myalgia—Methimazole—Graves' disease	0.00368	0.0243	CcSEcCtD
Boceprevir—CYP3A5—adipose tissue—Graves' disease	0.00365	0.0105	CbGeAlD
Boceprevir—Dysgeusia—Propylthiouracil—Graves' disease	0.0036	0.0238	CcSEcCtD
Boceprevir—CTSK—MHC class II antigen presentation—HLA-DRB1—Graves' disease	0.00347	0.00693	CbGpPWpGaD
Boceprevir—Thrombocytopenia—Methimazole—Graves' disease	0.00346	0.0228	CcSEcCtD
Boceprevir—CTSV—Class I MHC mediated antigen processing & presentation—HLA-E—Graves' disease	0.00337	0.00673	CbGpPWpGaD
Boceprevir—CTSL—Class I MHC mediated antigen processing & presentation—HLA-E—Graves' disease	0.00337	0.00673	CbGpPWpGaD
Boceprevir—Vertigo—Propylthiouracil—Graves' disease	0.0033	0.0218	CcSEcCtD
Boceprevir—Leukopenia—Propylthiouracil—Graves' disease	0.00329	0.0217	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00322	0.0212	CcSEcCtD
Boceprevir—Paraesthesia—Methimazole—Graves' disease	0.00317	0.0209	CcSEcCtD
Boceprevir—Arthralgia—Propylthiouracil—Graves' disease	0.00313	0.0207	CcSEcCtD
Boceprevir—Myalgia—Propylthiouracil—Graves' disease	0.00313	0.0207	CcSEcCtD
Boceprevir—Dyspepsia—Methimazole—Graves' disease	0.00311	0.0205	CcSEcCtD
Boceprevir—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00294	0.0194	CcSEcCtD
Boceprevir—CTSS—MHC class II antigen presentation—HLA-DRB1—Graves' disease	0.00286	0.00571	CbGpPWpGaD
Boceprevir—Urticaria—Methimazole—Graves' disease	0.0028	0.0185	CcSEcCtD
Boceprevir—Body temperature increased—Methimazole—Graves' disease	0.00279	0.0184	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00273	0.0181	CcSEcCtD
Boceprevir—Paraesthesia—Propylthiouracil—Graves' disease	0.00269	0.0178	CcSEcCtD
Boceprevir—Dyspepsia—Propylthiouracil—Graves' disease	0.00264	0.0174	CcSEcCtD
Boceprevir—Pruritus—Methimazole—Graves' disease	0.0025	0.0165	CcSEcCtD
Boceprevir—CTSL—Class I MHC mediated antigen processing & presentation—HLA-B—Graves' disease	0.0024	0.00479	CbGpPWpGaD
Boceprevir—CTSV—Class I MHC mediated antigen processing & presentation—HLA-B—Graves' disease	0.0024	0.00479	CbGpPWpGaD
Boceprevir—Urticaria—Propylthiouracil—Graves' disease	0.00238	0.0157	CcSEcCtD
Boceprevir—Body temperature increased—Propylthiouracil—Graves' disease	0.00237	0.0157	CcSEcCtD
Boceprevir—CMA1—Metabolism of proteins—B3GNT2—Graves' disease	0.0023	0.00459	CbGpPWpGaD
Boceprevir—CTSS—Class I MHC mediated antigen processing & presentation—HLA-E—Graves' disease	0.0023	0.00459	CbGpPWpGaD
Boceprevir—Vomiting—Methimazole—Graves' disease	0.00224	0.0148	CcSEcCtD
Boceprevir—CTSL—Class I MHC mediated antigen processing & presentation—HLA-A—Graves' disease	0.00223	0.00444	CbGpPWpGaD
Boceprevir—CTSV—Class I MHC mediated antigen processing & presentation—HLA-A—Graves' disease	0.00223	0.00444	CbGpPWpGaD
Boceprevir—Rash—Methimazole—Graves' disease	0.00223	0.0147	CcSEcCtD
Boceprevir—Dermatitis—Methimazole—Graves' disease	0.00222	0.0147	CcSEcCtD
Boceprevir—Headache—Methimazole—Graves' disease	0.00221	0.0146	CcSEcCtD
Boceprevir—CTSL—Innate Immune System—IFIH1—Graves' disease	0.00221	0.00441	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—IFIH1—Graves' disease	0.00221	0.00441	CbGpPWpGaD
Boceprevir—Pruritus—Propylthiouracil—Graves' disease	0.00212	0.014	CcSEcCtD
Boceprevir—Nausea—Methimazole—Graves' disease	0.0021	0.0138	CcSEcCtD
Boceprevir—ABCB1—pituitary gland—Graves' disease	0.00195	0.00561	CbGeAlD
Boceprevir—ABCB1—adipose tissue—Graves' disease	0.00194	0.00558	CbGeAlD
Boceprevir—Vomiting—Propylthiouracil—Graves' disease	0.00191	0.0126	CcSEcCtD
Boceprevir—Rash—Propylthiouracil—Graves' disease	0.00189	0.0125	CcSEcCtD
Boceprevir—Dermatitis—Propylthiouracil—Graves' disease	0.00189	0.0125	CcSEcCtD
Boceprevir—CTSV—Extracellular matrix organization—ICAM1—Graves' disease	0.00188	0.00375	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—ICAM1—Graves' disease	0.00188	0.00375	CbGpPWpGaD
Boceprevir—Headache—Propylthiouracil—Graves' disease	0.00188	0.0124	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—IFIH1—Graves' disease	0.00183	0.00365	CbGpPWpGaD
Boceprevir—Nausea—Propylthiouracil—Graves' disease	0.00178	0.0118	CcSEcCtD
Boceprevir—CMA1—Extracellular matrix organization—ICAM1—Graves' disease	0.00175	0.00349	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—HLA-E—Graves' disease	0.00174	0.00347	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—HLA-E—Graves' disease	0.00174	0.00347	CbGpPWpGaD
Boceprevir—ABCB1—thyroid gland—Graves' disease	0.00168	0.00483	CbGeAlD
Boceprevir—CTSL—Adaptive Immune System—HLA-E—Graves' disease	0.00167	0.00333	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—HLA-E—Graves' disease	0.00167	0.00333	CbGpPWpGaD
Boceprevir—CTSS—Class I MHC mediated antigen processing & presentation—HLA-B—Graves' disease	0.00164	0.00327	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CD40—Graves' disease	0.00163	0.00325	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—CD40—Graves' disease	0.00163	0.00325	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CTLA4—Graves' disease	0.00161	0.00321	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—CTLA4—Graves' disease	0.00161	0.00321	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—ICAM1—Graves' disease	0.00156	0.00311	CbGpPWpGaD
Boceprevir—CTSS—Class I MHC mediated antigen processing & presentation—HLA-A—Graves' disease	0.00152	0.00303	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—IFIH1—Graves' disease	0.00151	0.00301	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—HLA-E—Graves' disease	0.00144	0.00287	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—HLA-E—Graves' disease	0.00138	0.00276	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CD40—Graves' disease	0.00135	0.0027	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CTLA4—Graves' disease	0.00133	0.00266	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—HLA-DQB1—Graves' disease	0.00132	0.00264	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—HLA-DQB1—Graves' disease	0.00132	0.00264	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IFIH1—Graves' disease	0.00129	0.00257	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IFIH1—Graves' disease	0.00129	0.00257	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—ICAM1—Graves' disease	0.00128	0.00256	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—HLA-B—Graves' disease	0.00124	0.00247	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—HLA-B—Graves' disease	0.00124	0.00247	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CD8A—Graves' disease	0.00124	0.00247	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—CD8A—Graves' disease	0.00124	0.00247	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—HLA-B—Graves' disease	0.00119	0.00237	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—HLA-B—Graves' disease	0.00119	0.00237	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—HLA-E—Graves' disease	0.00119	0.00237	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—HLA-E—Graves' disease	0.00114	0.00227	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CD40—Graves' disease	0.00111	0.00222	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—HLA-A—Graves' disease	0.0011	0.0022	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—HLA-A—Graves' disease	0.0011	0.0022	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CTLA4—Graves' disease	0.0011	0.00219	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—HLA-DQB1—Graves' disease	0.0011	0.00219	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IFIH1—Graves' disease	0.00107	0.00213	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—HLA-B—Graves' disease	0.00103	0.00205	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CD8A—Graves' disease	0.00102	0.00204	CbGpPWpGaD
Boceprevir—CTSV—Immune System—HLA-E—Graves' disease	0.00101	0.00202	CbGpPWpGaD
Boceprevir—CTSL—Immune System—HLA-E—Graves' disease	0.00101	0.00202	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—HLA-DRB1—Graves' disease	0.00101	0.00201	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—HLA-DRB1—Graves' disease	0.00101	0.00201	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CD40—Graves' disease	0.000989	0.00197	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CD40—Graves' disease	0.000989	0.00197	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—HLA-B—Graves' disease	0.000985	0.00197	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CTLA4—Graves' disease	0.000975	0.00194	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CTLA4—Graves' disease	0.000975	0.00194	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—ICAM1—Graves' disease	0.000966	0.00193	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—ICAM1—Graves' disease	0.000966	0.00193	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—HLA-E—Graves' disease	0.000959	0.00191	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—CD40—Graves' disease	0.000938	0.00187	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—CTLA4—Graves' disease	0.000924	0.00184	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—HLA-A—Graves' disease	0.000913	0.00182	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—HLA-DQB1—Graves' disease	0.000903	0.0018	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IFIH1—Graves' disease	0.000878	0.00175	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—HLA-B—Graves' disease	0.000845	0.00169	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CD8A—Graves' disease	0.000844	0.00168	CbGpPWpGaD
Boceprevir—CTSK—Immune System—HLA-E—Graves' disease	0.000839	0.00167	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—HLA-DRB1—Graves' disease	0.000834	0.00166	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TSHR—Graves' disease	0.000823	0.00164	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CD40—Graves' disease	0.00082	0.00164	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—HLA-B—Graves' disease	0.000812	0.00162	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CTLA4—Graves' disease	0.000808	0.00161	CbGpPWpGaD
Boceprevir—CTSV—Immune System—HLA-DQB1—Graves' disease	0.000803	0.0016	CbGpPWpGaD
Boceprevir—CTSL—Immune System—HLA-DQB1—Graves' disease	0.000803	0.0016	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—ICAM1—Graves' disease	0.000801	0.0016	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	0.000761	0.00152	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—HLA-A—Graves' disease	0.000752	0.0015	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CD8A—Graves' disease	0.00075	0.0015	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CD8A—Graves' disease	0.00075	0.0015	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—CD4—Graves' disease	0.000739	0.00147	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—CD4—Graves' disease	0.000739	0.00147	CbGpPWpGaD
Boceprevir—CTSV—Immune System—HLA-B—Graves' disease	0.000721	0.00144	CbGpPWpGaD
Boceprevir—CTSL—Immune System—HLA-B—Graves' disease	0.000721	0.00144	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CD4—Graves' disease	0.00071	0.00142	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—CD4—Graves' disease	0.00071	0.00142	CbGpPWpGaD
Boceprevir—CTSS—Immune System—HLA-E—Graves' disease	0.000691	0.00138	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—HLA-DRB1—Graves' disease	0.000687	0.00137	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—HLA-B—Graves' disease	0.000684	0.00136	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IL2RA—Graves' disease	0.000676	0.00135	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IL2RA—Graves' disease	0.000676	0.00135	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CD40—Graves' disease	0.000675	0.00135	CbGpPWpGaD
Boceprevir—CTSV—Immune System—HLA-A—Graves' disease	0.000668	0.00133	CbGpPWpGaD
Boceprevir—CTSL—Immune System—HLA-A—Graves' disease	0.000668	0.00133	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—FASLG—Graves' disease	0.000668	0.00133	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CTLA4—Graves' disease	0.000665	0.00133	CbGpPWpGaD
Boceprevir—CTSK—Immune System—HLA-DQB1—Graves' disease	0.000665	0.00133	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—ICAM1—Graves' disease	0.000659	0.00131	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—FAS—Graves' disease	0.000644	0.00128	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—IL2RA—Graves' disease	0.000641	0.00128	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—HLA-A—Graves' disease	0.000633	0.00126	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CD8A—Graves' disease	0.000621	0.00124	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—CD4—Graves' disease	0.000613	0.00122	CbGpPWpGaD
Boceprevir—CTSV—Immune System—HLA-DRB1—Graves' disease	0.000611	0.00122	CbGpPWpGaD
Boceprevir—CTSL—Immune System—HLA-DRB1—Graves' disease	0.000611	0.00122	CbGpPWpGaD
Boceprevir—CTSK—Immune System—HLA-B—Graves' disease	0.000598	0.00119	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CD4—Graves' disease	0.000588	0.00117	CbGpPWpGaD
Boceprevir—CTSL—Immune System—ICAM1—Graves' disease	0.000586	0.00117	CbGpPWpGaD
Boceprevir—CTSV—Immune System—ICAM1—Graves' disease	0.000586	0.00117	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	0.000579	0.00115	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IL2RA—Graves' disease	0.00056	0.00112	CbGpPWpGaD
Boceprevir—CTSK—Immune System—HLA-A—Graves' disease	0.000554	0.0011	CbGpPWpGaD
Boceprevir—CTSS—Immune System—HLA-DQB1—Graves' disease	0.000548	0.00109	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CXCL10—Graves' disease	0.000532	0.00106	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CD8A—Graves' disease	0.000512	0.00102	CbGpPWpGaD
Boceprevir—CTSK—Immune System—HLA-DRB1—Graves' disease	0.000506	0.00101	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—CD4—Graves' disease	0.000505	0.00101	CbGpPWpGaD
Boceprevir—CTSS—Immune System—HLA-B—Graves' disease	0.000492	0.000982	CbGpPWpGaD
Boceprevir—CTSK—Immune System—ICAM1—Graves' disease	0.000486	0.000969	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CD4—Graves' disease	0.000485	0.000966	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IL2RA—Graves' disease	0.000461	0.00092	CbGpPWpGaD
Boceprevir—CTSS—Immune System—HLA-A—Graves' disease	0.000456	0.00091	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IFNG—Graves' disease	0.000446	0.000889	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IFNG—Graves' disease	0.000446	0.000889	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CD4—Graves' disease	0.000431	0.000859	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CD4—Graves' disease	0.000431	0.000859	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—IFNG—Graves' disease	0.000423	0.000843	CbGpPWpGaD
Boceprevir—CTSS—Immune System—HLA-DRB1—Graves' disease	0.000417	0.000831	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—IL2RA—Graves' disease	0.000406	0.00081	CbGpPWpGaD
Boceprevir—CTSS—Immune System—ICAM1—Graves' disease	0.0004	0.000798	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IL1B—Graves' disease	0.000398	0.000793	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IL1B—Graves' disease	0.000398	0.000793	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—IL1B—Graves' disease	0.000377	0.000752	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000376	0.00075	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IFNG—Graves' disease	0.00037	0.000737	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CD4—Graves' disease	0.000357	0.000712	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.00033	0.000658	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IL1B—Graves' disease	0.00033	0.000657	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000318	0.000634	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IFNG—Graves' disease	0.000304	0.000607	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CD4—Graves' disease	0.000294	0.000586	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—TNF—Graves' disease	0.000274	0.000545	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IL1B—Graves' disease	0.000271	0.000541	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GC—Graves' disease	0.000251	0.000501	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—B3GNT2—Graves' disease	0.00019	0.00038	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GC—Graves' disease	0.00019	0.000378	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—B3GNT2—Graves' disease	0.000144	0.000286	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000135	0.000269	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GC—Graves' disease	0.000117	0.000233	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—B3GNT2—Graves' disease	8.85e-05	0.000176	CbGpPWpGaD
